PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: A meta-analysis of 19 studies comprising 3,003 patients

Marilena Crescente; Augusto Di Castelnuovo; Licia Iacoviello; Giovanni de Gaetano; Chiara Cerletti

doi:10.1160/TH08-03-0130

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2008; 99(06): 1129-1131
DOI: 10.1160/TH08-03-0130

Letters to the Editor

Schattauer GmbH

PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: A meta-analysis of 19 studies comprising 3,003 patients

Marilena Crescente

¹Research Laboratories, “John Paul II” Centre for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso, Italy

,

Augusto Di Castelnuovo

¹Research Laboratories, “John Paul II” Centre for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso, Italy

,

Licia Iacoviello

¹Research Laboratories, “John Paul II” Centre for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso, Italy

,

Giovanni de Gaetano

¹Research Laboratories, “John Paul II” Centre for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso, Italy

,

Chiara Cerletti

¹Research Laboratories, “John Paul II” Centre for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso, Italy

› Author Affiliations

Abstract

Full Text

References

References
1 Crescente M, Di Castelnuovo A, Iacoviello L. et al. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost 2008; 99: 14-26.
2 Reny JL, de Moerloose P, Dauzat M. et al. Use of the PFA-100 trade mark closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2008; 6: 444-450.
3 Krasopoulos G, Brister SJ, Beattie WS. et al. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. Br Med J 2008; 336: 195-198.
4 Snoep JD, Hovens MM, Eikenboom JC. et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 1593-1599.
5 Di Castelnuovo A, Soccio M, Iacoviello L. et al. “The C242 T polymorphism of the p22phox component of NAD(P)H oxidase and vascular risk. Two case-control studies and meta-analyses. Thromb Haemost 2008; 99: 594-601.